Harmonic Pharma, Institut Curie deal
Harmonic Pharma, Villers les Nancy, France Institut Curie, Paris, France Business: Cancer Harmonic partnered with Curie-Cancer, part of Institut Curie, to develop molecules in the biotech’s pipeline to treat breast, lung and eye cancers. Harmonic will receive access to mouse cancer models from the institute for screening its compouds against an undisclosed cellular membrane receptor target.
Curie-Cancer and Harmonic Pharma sign partnership agreement
Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities and Harmonic Pharma, which is developing solutions for extending the therapeutic application of compounds already on the market, announce today that they have entered into a research collaboration aimed at exploring the anti-cancer activity of several molecules in Harmonic Pharma’s portfolio.